ReviewExpert review of respiratory medicine2011
Pulmonary arterial hypertension associated with systemic sclerosis.
Review in Expert review of respiratory medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Trial
- Article
- Role of Left Ventricular Dysfunction in Systemic Sclerosis-Related Pulmonary Hypertension.Chest · 2024Observational
- A Rare Presentation of Systemic Sclerosis.Cureus · 2023Article
- Clinical features of pulmonary arterial hypertension associated with systemic sclerosis.Frontiers in medicine · 2023Review
- The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure.Circulation research · 2022Review
- Editorial: Oxidative Stress in Cardiovascular Diseases and Pulmonary Hypertension.Frontiers in cardiovascular medicine · 2022Article
- Low-Dose Dobutamine Stress Echocardiography for the Early Detection of Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis Whose Resting Echocardiography Is Non-Diagnostic for Pulmonary Hypertension.Journal of clinical medicine · 2021Article
- The Role of Exercise Doppler Echocardiography to Unmask Pulmonary Arterial Hypertension in Selected Patients with Systemic Sclerosis and Equivocal Baseline Echocardiographic Values for Pulmonary Hypertension.Diagnostics (Basel, Switzerland) · 2021Article
- Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers.Journal of scleroderma and related disorders · 2019Article
- Intravenous sildenafil acutely improves hemodynamic response to exercise in patients with connective tissue disease.PloS one · 2018Article
- Novel classification for global gene signature model for predicting severity of systemic sclerosis.PloS one · 2018Article
- Lung Manifestations in the Rheumatic Diseases.Chest · 2017Review
- Prevalence of Pulmonary Arterial Hypertension in Korean Adult Patients with Systemic Sclerosis: Result of a Pilot Echocardiographic Screening Study.Journal of cardiovascular ultrasound · 2016Article
- Survival protection by bodyweight in isolated scleroderma-related pulmonary artery hypertension.Internal and emergency medicine · 2016Article
- Identification of Rare Variants in ATP8B4 as a Risk Factor for Systemic Sclerosis by Whole-Exome Sequencing.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Heart rate recovery is an important predictor of outcomes in patients with connective tissue disease-associated pulmonary hypertension.Pulmonary circulation · 2015Article
- Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans.Medicine · 2014Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Systemic sclerosis (SSc) is commonly complicated by pulmonary arterial hypertension (PAH), which is a leading cause of death in the SSc patient population. Owing to the fact that the risk of developing pulmonary hypertension is high, screening is important, although the optimal modality remains to be defined. Furthermore, despite recent advances in therapy for PAH, the response to these interventions in patients with PAH with SSc has been discouraging. The lack of clinical response to these therapies may merely reflect the limitations of traditionally employed PAH outcome measures in SSc-PAH patients or highlight the heterogeneity of the disease manifestations within SSc. Importantly, since extrapulmonary involvement of the GI tract and kidneys by SSc limit candidacy for lung transplantation, new therapies that target abnormal cellular proliferation in the pulmonary vasculature are currently under investigation and may be particularly relevant to SSc-PAH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.